Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts

Authors: Amira Ziouèche-Mottet, Gilles Houvenaeghel, Jean Marc Classe, Jean Rémi Garbay, Sylvia Giard, Hélène Charitansky, Monique Cohen, Catherine Belichard, Christelle Faure, Elisabeth Chéreau Ewald, Delphine Hudry, Pierre Azuar, Richard Villet, Pierre Gimbergues, Christine Tunon de Lara, Agnès Tallet, Marie Bannier, Mathieu Minsat, Eric Lambaudie, Michel Resbeut

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

We wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence.

Methods

We undertook a retrospective study examining two cohorts. The first cohort was multicentric (G3S) and contained 7580 patients. The second cohort was monocentric (cohort 2) comprising 4445 patients. All patients underwent conservative surgery followed by external radiotherapy for invasive breast cancer (T0–T3, N0–N1) between 1980 and 2005. Within each cohort, two groups were isolated according to the inclusion criteria of the TARGIT A study (T group) and RIOP trial (R group).
In the multicentric cohort (G3S) eligible patients for TARGIT A and RIOP trials were T1E and R1E subgroups, respectively. In cohort number 2, the corresponding subgroups were T2E and R2E. Similarly, non-eligible patients were T1nE, R1nE and T2nE, and R2nE.
The eligible groups in the TARGIT A study that were not eligible in the RIOP trial (TE–RE) were also studied. The proportion of patients eligible for TARGIT was calculated according to the criteria of each study. A comparison was made of the 5-year survival without local or locoregional recurrence between the TE versus TnE, RE versus RnE, and RE versus (TE–RE) groups.

Results

In G3S and cohort 2, the proportion of patients eligible for TARGIT was, respectively, 53.2% and 33.9% according the criteria of the TARGIT A study, and 21% and 8% according the criteria of the RIOP trial. Survival without five-year locoregional recurrence was significantly different between T1E and T1nE groups (97.6% versus 97% [log rank =0.009]), R1E and R1nE groups (98% versus 97.1% [log rank =0.011]), T2E and T2nE groups (96.6% versus 93.1% [log rank <0. 0001]) and R2E and R2nE groups (98.6% versus 94% [log rank =0.001]). In both cohorts, no significant difference was found between RE and (TE–RE) groups.

Conclusions

Almost 50% of T0-2 N0 patients could be eligible for TARGIT.
Appendix
Available only for authorised users
Literature
1.
2.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011, 378 (9804): 1707-1716.CrossRefPubMed
3.
Cowen D, Jacquemier J, Houvenaeghel G, Viens P, Puig B, Bardou VJ, Resbeut M, Maraninchi D: Local and distant recurrence after conservative management of “very low-risk” breast cancer are dependent events: a 10-year follow-up. Int J Radiat Oncol Biol Phys. 1998, 41 (4): 801-807. 10.1016/S0360-3016(98)00144-8.CrossRefPubMed
4.
Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M, Hilaris B, Saunders C, Williams NR, Brew-Graves C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Sütterlin M, Bulsara M, Joseph D: Long-term results of targeted intraoperative radiotherapy Targit) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011, 81 (4): 1091-1097. 10.1016/j.ijrobp.2010.07.1996.CrossRefPubMed
5.
Vaidya JS, Baum M, Tobias JS, Wenz F, Massarut S, Keshtgar M, Hilaris B, Saunders C, Williams NR, Brew-Graves C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Sütterlin M, Bulsara M, Joseph D: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010, 376 (9735): 91-102. 10.1016/S0140-6736(10)60837-9.CrossRefPubMed
6.
Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H, Cohen M, Belichard C, Faure C, Uzan S, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Lambaudie E, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Esterni B: Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. Ann Oncol. 2014, [Epub ahead of print]
7.
Howell LP, Gandour-Edwards R, O’Sullivan D: Application of the Scarff-Bloom-Richardson tumor grading system to fine-needle aspirates of the breast. Am J Clin Pathol. 1994, 101 (3): 262-265.CrossRefPubMed
8.
Chen SC, Chen MF, Hwang TL, Chao TC, Lo YF, Hsueh S, Chang JT, Leung WM: Prediction of supraclavicular lymph node metastasis in breast carcinoma. Int J Radiat Oncol Biol Phys. 2002, 52: 614-619. 10.1016/S0360-3016(01)02680-3.CrossRefPubMed
9.
Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N: Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2004, 22: 4247-4254. 10.1200/JCO.2004.01.042.CrossRefPubMed
10.
Auberdiac P, Cartier L, Chargari C, Zioueche A, Mélis A, de Laroche G, Castro Pena P, Kirova YM, Magné N: Supra- and infraclavicular lymph node irradiation in breast cancer patients: state of the art. Cancer Radiother. 2012, 16 (3): 237-242. 10.1016/j.canrad.2012.02.005. quiz 243. doi:10.1016/j.canrad.2012.02.005. Epub 2012 Apr 30CrossRefPubMed
11.
Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M, Flyger H, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg H, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M: Abstract S4-2: Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial- updated analysis of local recurrence and first analysis of survival. Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. Cancer Res. 2012, 72 (24 Suppl):
12.
Shah C, Wilkinson JB, Lanni T, Jawad M, Wobb J, Fowler A, Wallace M, Chen P, Grills IS, Vicini F: Five-year outcomes and toxicities using 368 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Clin Breast Cancer. 2013, 13 (3): 206-211. 10.1016/j.clbc.2012.09.020.CrossRefPubMed
13.
Ferraro DJ, Garsa AA, DeWees TA, Margenthaler JA, Naughton M, Aft R, Gillanders WE, Eberlein T, Matesa MA, Zoberi I: Comparison of accelerated partial breast irradiation via multicatheter interstitial brachytherapy versus whole breast radiation. Radiat Oncol. 2012, 7 (1): 53-10.1186/1748-717X-7-53.CrossRefPubMedPubMedCentral
14.
Leonardi MC, Maisonneuve P, Mastropasqua MG, Morra A, Lazzari R, Rotmensz N, Sangalli C, Luini A, Veronesi U, Orecchia R: How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology. Int J Radiat Oncol Biol Phys. 2012, 83 (3): 806-813. 10.1016/j.ijrobp.2011.08.014.CrossRefPubMed
15.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010, 28 (10): 1684-1691. 10.1200/JCO.2009.24.9284.CrossRefPubMed
16.
Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ: Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012, 133 (3): 831-841. 10.1007/s10549-011-1891-6.CrossRefPubMed
17.
Sanghani M, Truong PT, Raad RA, Niemierko A, Lesperance M, Olivotto IA, Wazer DE, Taghian AG: Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol. 2010, 28 (5): 718-722. 10.1200/JCO.2009.22.6662.CrossRefPubMedPubMedCentral
18.
Van Nes JG, Putter H, van Hezewijk M, Hille ET, Bartelink H, Collette L, van de Velde CJ, EORTC Breast Cancer Group: Tailored follow-up for early 391 breast cancer patients: a prognostic index that predicts locoregional recurrence. Eur J Surg Oncol. 2010, 36 (7): 617-624. 10.1016/j.ejso.2010.05.010.CrossRefPubMed
19.
Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009, 74 (4): 987-1001. 10.1016/j.ijrobp.2009.02.031.CrossRefPubMed
20.
Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, Hildebrandt G, Niehoff P, Guinot JL, Guedea F, Johansson B, Ott OJ, Major T, Strnad V, GEC-ESTRO breast cancer working group: Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010, 94: 264-273. 10.1016/j.radonc.2010.01.014.CrossRefPubMed
21.
Czechura T, Winchester DJ, Pesce C, Huo D, Winchester DP, Yao K: Accelerated partial-breast irradiation versus whole breast irradiation for early-stage breast cancer patients undergoing breast conservation, 2003–2010: a report from the national cancer data base. Ann Surg Oncol. 2013, 20 (10): 3223-3232. 10.1245/s10434-013-3154-8.CrossRefPubMed
Metadata
Title
Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts
Authors
Amira Ziouèche-Mottet
Gilles Houvenaeghel
Jean Marc Classe
Jean Rémi Garbay
Sylvia Giard
Hélène Charitansky
Monique Cohen
Catherine Belichard
Christelle Faure
Elisabeth Chéreau Ewald
Delphine Hudry
Pierre Azuar
Richard Villet
Pierre Gimbergues
Christine Tunon de Lara
Agnès Tallet
Marie Bannier
Mathieu Minsat
Eric Lambaudie
Michel Resbeut
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-868

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Study protocol

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab

Research article

MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis

Research article

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

Research article

Space-time clusters of breast cancer using residential histories: A Danish case–control study

Research article

Combined use of the automated breast volume scanner and the US elastography for the differentiation of benign from malignant lesions of the breast

Research article

MiR-181b sensitizes glioma cells to teniposide by targeting MDM2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits